CytomX Therapeutics reported unaudited financial results for the third quarter ended September 30, 2026. Total revenue decreased to $1.7 million from $6.0 million in the prior year period, primarily due to the conclusion of a performance obligation under an Astellas collaboration. The company ended the quarter with $348.0 million in cash, cash equivalents, and investments, providing a runway into the second half of 2028. Operating expenses rose to $25.2 million from $21.7 million, driven by increased personnel costs and rent associated with a move to new headquarters. The company also provided updates on its lead candidate Varseta-M, noting FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer and plans to initiate expansion cohorts in other gastrointestinal cancers.
